Related Experiment Videos
Accelerated chemotherapy for poor prognosis germ cell tumours
A Horwich1, D P Dearnaley, A Norman
1Urological Oncology Unit, Royal Marsden Hospital, Sutton, Surrey, UK.
European Journal of Cancer (Oxford, England : 1990)
|January 1, 1994
Summary
A novel chemotherapy regimen (C-BOP/BEP) shows promising results for metastatic germ cell tumors. This intensive schedule achieved a 90% two-year survival rate in a pilot study for high-risk patients.
Area of Science:
- Oncology
- Medical Research
Background:
- Metastatic germ cell tumors (GCTs) in patients with poor prognosis present a significant clinical challenge.
- Rapid tumor proliferation necessitates aggressive treatment strategies.
Purpose of the Study:
- To evaluate an innovative, dose-intensive chemotherapy schedule for poor-prognosis metastatic GCT patients.
- To assess the feasibility and efficacy of a novel C-BOP/BEP regimen.
Main Methods:
- A pilot study involving 21 patients with adverse GCT presentations.
- Treatment comprised a C-BOP regimen followed by three cycles of bleomycin, etoposide, and cisplatin (BEP).
- The regimen featured an extremely short intercycle interval to combat tumor proliferation.
Main Results:
- The 2-year overall survival rate was 90% (95% CI = 77-100%).
- One patient died of disease, one from a treatment complication, and one relapsed but achieved remission.
- Median follow-up for survivors was 36 months.
Conclusions:
- The dose-intensive C-BOP/BEP chemotherapy schedule demonstrates potential as an improvement over standard treatments for poor-prognosis metastatic GCTs.
- Further assessment in a multicenter setting is warranted to validate these findings.